Search Results - adoptive+cell+transfer

8 Results

Sort By:

Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)

Abstract: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize unique antigens expressed by cancer cells (“neoantigens”). Neoantigen specific TIL administration in patients has resulted in long term regression of certain metastatic cancers. However, one of the challenges of ACT and engineered T cell receptor (TCR) therapies...

Published: 4/8/2024 | Inventor(s): Sri Krishna, Paul Robbins, Rami Yoseph, James Yang, Kenichi Hanada, Frank Lowery, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptor, TCR, TIL, tumor, Tumor Infiltrating Lymphocyte

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer

Abstract: Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes autologous, antitumor T cells to attack tumors through recognition of tumor-specific mutations, or neoantigens. A major hurdle in the development of ACT is the exhausted phenotype exhibited by many neoantigen-specific T cells, which limits their efficacy...

Published: 4/8/2024 | Inventor(s): Sri Krishna, Zhiya Yu, Kenichi Hanada, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Krishna, Neoantigen, Rosenberg, T-Cell Receptor, TCR, Vaccine

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Inhibition of T Cell Differentiation and Senescence by Overexpression of Transcription Factor c-Myb

Abstract: Adoptive Cell Therapy (ACT) is a promising technique that uses a patient's own T cells to treat cancer. The process requires removing and engineering a patient's T cells to express a chimeric antigen receptor (CAR) or T cell receptor (TCR) that targets a specific cancer antigen. When the modified T cells are reintroduced into the patient,...

Published: 4/8/2024 | Inventor(s): Sanjivan Gautam, Yun Ji, Luca Gattinoni

Keywords(s): act, Adoptive Cell Transfer, CANCER, CAR, chimeric antigen receptor, Gattinoni, Immunotherapy, Infectious Disease, Stem Cell, T cell, T Cell Receptor, TCR

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients

Abstract: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize antigens expressed by cancer cells (neoantigens). Neoantigen specific TIL administration in patients has resulted in long-term regression of certain metastatic cancers. However, current procedures for TIL therapy are highly invasive, labor-intensive, and...

Published: 4/8/2024 | Inventor(s): Rami Yoseph, Paul Robbins, Frank Lowery, Sri Krishna, Amy Copeland, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptors, TCRs, TILS, Tumor Infiltrating Lymphocytes

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Method for Direct Identification of Neoantigen-Specific TCRs from Tumor Specimens by High-Throughput Single-Cell Sequencing

Abstract: Cancer immunotherapy approaches, such as adoptive cell transfer (ACT), proved effective against many cancer types. Yet, post-treatment analyses of ACT have suggested that efficacy may be enhanced by increasing the percentage of neoantigen-reactive T cells in the infused product. Neoantigens are new proteins that form on cancer cells when certain...

Published: 4/8/2024 | Inventor(s): Yong-Chen Lu, Zhili Zheng, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, Single Cell Sequencing, T Cell Receptor, TCR

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing

Calcium (Ca2+) Flux-Dependent Method to Detect and Isolate Tumor Reactive T Cell Receptors (TCRs)

Abstract: T cells with T cell receptors (TCRs) for cancer-specific antigens are used for adoptive cell therapy (ACT), wherein a patient’s T cells are redirected against their own cancer. However, these isolated T cells may require further ex vivo manipulation to enhance their anti-tumor activity. The ex vivo manipulation of these T cells, or the selection...

Published: 4/8/2024 | Inventor(s): Douglas Palmer, Anna Pasetto, Nicholas Restifo, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, CA2+, Calcium Ion, Immunotherapy, Rosenberg, T Cell Receptor, TCR, tumor

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Use of Heterodimeric IL-15 in Adoptive Cell Transfer

Abstract: Adoptive cell transfer (ACT) is a promising immunotherapeutic approach for cancer treatment. During ACT, if a patient is subjected to lymphodepletion prior to cell transfer, there is an observed improvement in a patient’s response to treatment. However, lymphodepletion is associated with detrimental effects, including severe immune dysfunction...

Published: 5/22/2024 | Inventor(s): George Pavlakis, Barbara Felber, Christina Bergamaschi

Keywords(s): act, Adoptive Cell Transfer, HetIL-15, IL-15, Immunotherapy, Interleukin 15, Lymphodepletion, Receptor Alpha Complex

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation

Abstract: Mutation of amino acid 61of the neuroblastoma rat sarcoma viral oncogene homologue (NRAS) is a known driver of oncogenesis in melanoma. Glutamine (Q) to lysine (K) mutation at this position of NRAS is prevalent in approximately 10% of all melanoma cases and associated with aggressive tumors and low patient survival. Therefore, Q61K mutated...

Published: 4/8/2024 | Inventor(s): Paul Robbins, Steven Rosenberg, Gabriel Ivey, Almin Latani

Keywords(s): act, Adoptive Cell Transfer, HLA, Human Leukocyte Antigen, immuno-oncology, Immunotherapy, Neuroblastoma Rat Sarcoma Viral Oncogene, NRAS, Robbins, Rosenberg, T-Cell Receptor, TCR

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing